The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke, vascular disease, age 65-74 years, female gender) score is used to estimate thromboembolic risk in atrial fibrillation (AF). Its usefulness in predicting in-stent restenosis (ISR) is unknown. We evaluated the predictive value of the CHA2DS2-VASc score in AF-free patients who have undergone stent implantation. A total of 1350 patients who underwent coronary angiography and successful bare-metal stent implantation were analyzed. The CHA2DS2-VASc score was calculated before percutaneous coronary intervention, and the association between the score and ISR was investigated. Patients (n = 700; mean age: 61.4 [8.7] years, 63% men) were divided in 2 subgroups according to the presence of ISR; 265 of 700 patients had ISR. Mean CHA2DS2-VASc score was significantly higher in the ISR (+) group than the ISR (−) group (3.7 [1.8] vs 2.1 [1.4], P < .001). According to multivariate logistic regression analysis, diabetes, hyperlipidemia, smoking, stent length, and CHA2DS2-VASc score were independent predictors of ISR. In conclusion, the CHA2DS2-VASc score may be useful as a new and simple tool to predict ISR.
DangasGDClaessenBECaixetaASanidasEAMintzGSMehranR. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907.
2.
AlfonsoFByrneRARiveroFKastratiA. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–2673.
3.
SiontisGCStefaniniGGMavridisD, et al.Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655–664.
4.
UysalOKTurkogluCDuranM, et al.Predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in ST segment elevation myocardial infarction. Kardiol Pol. 2016;74(9):954–960.
5.
KhouzamRNShaheenMAzizRKIbebuoguUN. The important role of inflammatory biomarkers pre and post bare–metal and drug–eluting stent implantation. Can J Cardiol. 2012;28(6):700–705.
6.
YilmazSAkbogaMKSenF, et al.Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomark Med. 2016;10(9):959–966.
7.
CammAJLipGYDe CaterinaR, et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–2747.
8.
OrvinKBentalTAssaliALevEIVaknin-AssaHKornowskiR. Usefulness of the CHA2DS2-VASC score to predict adverse outcomes in patients having percutaneous coronary intervention. Am J Cardiol. 2016;117(9):1433–1438.
9.
HuangSSChenYHChanWLHuangPHChenJWLinSJ. Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction. Am J Cardiol. 2014;114(9):1309–1314.
10.
ReinerŽCatapanoALDe BackerG, et al.ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32(14):1769–1818.
11.
American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes care. 2015;38(suppl 1):8–16.
12.
LevineGNBatesERBlankenshipJC, et al.2011ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–e122.
13.
SmithSJrDoveJJacobsA, et al.ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37(8):2215–2239.
14.
SmithSCDoveJTJacobsAK, et al.ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) 333: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 2001;37(8):2239–2239.
15.
NiccoliGMontoneRAFerranteGCreaF. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56(22):1783–1793.
16.
AbizaidAKornowskiRMintzGS, et al.The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32(3):584–589.
17.
HoffmannRMintzGSDussaillantGR, et al.Patterns and mechanisms of in-stent restenosis. Circulation. 1996;94(6):1247–1254.
18.
FerranteGNiccoliGBiasucciLM, et al.Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9(3):156–165.
19.
PietersmaAKofflardMde WitLEA, et al.Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91(5):1320–1325.
20.
RahelBMVisserenFLSuttorpMJ, et al.Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60(1):136–140.
21.
TürkerSGüneriSAkdenizB, et al.Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol. 2006;97(2):198–202.
22.
CapodannoDRossiniRMusumeciG, et al.Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol. 2015;199:319–325.
23.
PoçiDHartfordMKarlssonTHerlitzJEdvardssonNCaidahlK. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141(6):1431–1440.
24.
TaşolarHÇetinMBallıM, et al.CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol. 2016;16(10):742–748.
25.
UeharaMFunabashiNTakaokaH, et al.CHA2DS2-VASc score is a useful-predictor of not prognosis but coronary-arteriosclerosis in chronic atrial-fibrillation compared with CHADS2 score: a two-center study of 320-slice CT, part 2. Int J Cardiol. 2014;177(2):368–373.
26.
KurtulAYarliogluesMDuranM. Predictive value of CHA2DS2-VASC score for contrast-induced nephropathy after percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2016;119(6):819–825.
27.
AkbogaMKYalcinRSahinarslanAYilmaz DemirtasCAbaciA. Effect of serum YKL-40 on coronary collateral development and SYNTAX score in stable coronary artery disease. Int J Cardiol. 2016;224:323–327.
28.
YilmazSSenFAkbogaMK, et al.The relationship between resting heart rate and SYNTAX score in patients with stable coronary artery disease. Angiology. 2017;68(2):168–173.
29.
AkyelASahinarslanAKiziltuncE, et al.Neutrophil gelatinase-associated lipocalin levels in isolated coronary artery ectasia. Can J Cardiol. 2011;27(6):773–778.
